Lipid profile interpretation

Overall pattern

• The main abnormality is the LDL-C of about 200 mg/dL.
• Triglycerides are also mildly elevated.
• HDL is not low, which is favorable, but an HDL of 51 does not cancel the risk from LDL of 200.
• Non-HDL cholesterol of 234.6 mg/dL means there is a high total burden of cholesterol carried in potentially atherogenic particles, including LDL, VLDL remnants, and IDL.

How cholesterol is formed

• Cell membranes
• Steroid hormones such as cortisol, testosterone, and estrogen
• Vitamin D production
• Bile acids and bile salts, which help digest dietary fats

1. Intracellular cholesterol synthesis

Acetyl-CoA
   ↓
Acetoacetyl-CoA
   ↓  HMG-CoA synthase
HMG-CoA
   ↓  HMG-CoA reductase + NADPH
Mevalonate
   ↓
Isoprene units
   ↓
Farnesyl pyrophosphate
   ↓
Squalene
   ↓
Lanosterol
   ↓
Cholesterol

The key control point

• It is the rate-limiting step of cholesterol synthesis.
• If a liver cell senses low intracellular cholesterol, it activates SREBP-2 and increases cholesterol synthesis and LDL-receptor production.
• If intracellular cholesterol is high, HMG-CoA reductase production and activity fall.
• AMPK-mediated phosphorylation inhibits the enzyme during low-energy states.
• Insulin tends to favor cholesterol synthesis, whereas glucagon and low-energy signaling oppose it.
• Statins reduce cholesterol production by competitively inhibiting HMG-CoA reductase. The liver then increases LDL receptors and removes more LDL from the blood.

2. Cholesterol leaves the liver in lipoproteins

Dietary pathway

Food fat and cholesterol
   ↓
Intestinal absorption
   ↓
Chylomicrons
   ↓  lipoprotein lipase (LPL)
Fatty acids delivered to muscle and adipose tissue
   ↓
Chylomicron remnants
   ↓
Liver uptake

Liver-to-blood pathway: the pathway most relevant to your LDL

Liver
   ↓
VLDL: triglyceride-rich particle containing ApoB-100
   ↓  LPL removes triglycerides
IDL: VLDL remnant
   ↓
Some IDL is taken back up by the liver via ApoE/LDL-receptor pathways
   ↓  further triglyceride removal
LDL: cholesterol-rich particle containing ApoB-100
   ↓
LDL receptor-mediated liver uptake

3. Why LDL becomes harmful

1. They enter the artery wall.
2. They can be oxidized, glycated, or otherwise modified.
3. Macrophages take up modified LDL through scavenger receptors.
4. Macrophages become cholesterol-filled foam cells.
5. Foam cells form fatty streaks and later atherosclerotic plaque.
6. Plaque can narrow arteries or rupture, causing heart attack or stroke.

Why this particular lipid pattern can occur

A. Primary or genetic causes: important to consider in your case

1. Familial hypercholesterolemia

• LDLR gene variants: fewer or less effective LDL receptors
• APOB gene variants: ApoB-100 does not bind the LDL receptor normally
• PCSK9 gain-of-function variants: more LDL receptors are degraded, so less LDL is cleared

Reduced hepatic LDL clearance
             ↓
LDL remains in blood longer
             ↓
Markedly raised LDL cholesterol
             ↓
Higher lifetime atherosclerosis risk

• Parent, sibling, or child with LDL-C above 190 mg/dL
• A heart attack, angioplasty, stroke, or sudden cardiac death at a young age
• Premature coronary disease in a man before 55 years or a woman before 65 years
• Tendon xanthomas, especially thickening over the Achilles tendon or knuckles
• Corneal arcus at a young age
• Very high cholesterol in several family members

2. Polygenic hypercholesterolemia

3. Familial combined hyperlipidemia

• Elevated LDL
• Elevated triglycerides
• Elevated ApoB
• Variable patterns among relatives

B. Dietary and lifestyle contributors

Factors that raise LDL

• High saturated-fat intake: ghee, butter, cream, cheese, fatty red meat, processed meats, coconut oil or palm oil in large quantities
• Trans fats: bakery shortening, repeatedly heated commercial frying oils, some packaged snacks and pastries
• Weight gain, especially abdominal fat
• A diet high in refined carbohydrates together with excess calories
• High dietary cholesterol may contribute in some people, though saturated and trans fats usually have a larger LDL effect
• Ketogenic or very-high-fat diets in susceptible people
• Rapid weight loss or major shifts in diet can temporarily alter lipids

Factors that raise triglycerides

• Excess calories and abdominal obesity
• Insulin resistance or prediabetes
• Diabetes, especially if glucose control is poor
• Sugary drinks, sweets, refined rice/flour products, bakery foods
• Alcohol, even if LDL is the predominant issue
• Physical inactivity
• Fatty liver disease
• High-fructose intake
• Some medications

C. Medical conditions that should be ruled out

D. Medicines and substances that can raise lipids

• Corticosteroids, such as prednisolone
• Thiazide diuretics
• Some beta-blockers
• Cyclosporine or tacrolimus
• Retinoids, such as isotretinoin or acitretin
• Certain HIV antiretroviral medicines
• Some antipsychotic medicines
• Oral estrogens in some contexts
• Immunosuppressive medicines
• Anabolic-androgenic steroids or bodybuilding products
• Excess alcohol

Is this result accurate?

• VLDL = triglycerides ÷ 5
  172.78 ÷ 5 = 34.56 mg/dL
• Calculated LDL = total cholesterol - HDL - VLDL
  285.7 - 51.1 - 34.56 = 200.04 mg/dL
• Non-HDL = total cholesterol - HDL
  285.7 - 51.1 = 234.6 mg/dL

What to do next

Arrange a clinician appointment promptly

Useful next tests

1. Repeat fasting lipid profile, ideally after 9-12 hours fasting, if the current test was not fasting.
2. Apolipoprotein B (ApoB): better reflects the number of atherogenic particles.
3. Lipoprotein(a), or Lp(a): should generally be checked at least once in adulthood, particularly with LDL this high or a family history of early cardiovascular disease.
4. HbA1c and fasting glucose: check diabetes or prediabetes.
5. TSH, with free T4 if abnormal: exclude hypothyroidism.
6. Liver panel: ALT, AST, alkaline phosphatase, bilirubin.
7. Kidney assessment: creatinine, eGFR, urine routine, urine albumin/protein.
8. Blood pressure, BMI, waist circumference, smoking/vaping status.
9. Family lipid testing if FH is suspected.

Treatment discussion

Practical lifestyle actions starting now

Food pattern

• Replace ghee, butter, cream, fatty meat, deep-fried foods, bakery items, and processed meats with unsaturated fats such as nuts, seeds, groundnut oil, mustard oil, olive oil, fish, and avocado where practical.
• Avoid trans-fat-containing packaged bakery and fried foods.
• Increase soluble fibre: oats, barley, beans, chickpeas, lentils, okra, apples, citrus fruits, psyllium husk if appropriate.
• Choose vegetables, whole grains, pulses, fruits, and minimally processed protein sources.
• Reduce sugary drinks, desserts, fruit juice, refined flour foods, and frequent large portions of white rice if triglycerides or insulin resistance are concerns.
• Minimize alcohol, especially while triglycerides are elevated.
• Avoid “keto,” butter coffee, or very-high-fat diets until you have discussed them with your clinician.

Activity and weight

• Aim for at least 150 minutes weekly of moderate aerobic activity, such as brisk walking, plus resistance exercise on 2 days weekly if medically safe.
• If overweight, gradual weight loss can improve triglycerides, insulin resistance, fatty liver risk, and non-HDL cholesterol.
• Avoid smoking, vaping, and tobacco.

Bottom line

1. Primary genetic or polygenic high LDL, including familial hypercholesterolemia
2. Diet and weight-related contribution
3. Insulin resistance, prediabetes, diabetes, or fatty liver
4. Hypothyroidism
5. Kidney disease, nephrotic syndrome, or cholestatic liver disease
6. Medication, anabolic steroid, supplement, or alcohol effects

What your results most likely mean

Your probable untreated LDL range is about 175-200 mg/dL

Natural / untreated LDL-C: roughly 175-200 mg/dL
      ↓
Rosuvastatin 5 mg taken consistently
      ↓
LDL-C can reach about 94 mg/dL

The June 2025 response was very good

• Absolute decrease: 98 mg/dL
• Percentage decrease: 51%

• Complete statin resistance
• A homozygous LDL-receptor disorder
• An LDL level that cannot be lowered with standard therapy

Why was LDL 156 mg/dL in May 2026 despite “treatment”?

1. Inconsistent dosing
   • Missed tablets, taking it only a few days per week, travel, running out of medication, or taking breaks because of symptoms.
   • This is the most common explanation when the same dose previously worked very well.
2. The medication may have been stopped shortly before the May blood test
   • Rosuvastatin does not permanently lower LDL after it is stopped.
   • After stopping, LDL begins moving back toward the untreated level. Fifteen days off rosuvastatin before the August test is long enough that the result should be treated as effectively untreated.
3. A different tablet, dose, brand, or dispensing issue
   • Confirm the packet, strength, expiry date, and that it was truly rosuvastatin 5 mg, not a similarly named product or a substitute.
4. New secondary cause increasing LDL
   • Hypothyroidism is particularly important.
   • Weight gain, high saturated-fat intake, ketogenic/high-fat diet, diabetes or insulin resistance, kidney disease with urinary protein loss, and cholestatic liver disease can contribute.
   • Certain drugs can worsen lipids, including corticosteroids, retinoids, cyclosporine, some antipsychotics, thiazides, and some beta-blockers.
5. The May sample was nonfasting or triglycerides were higher
   • This can affect a calculated LDL somewhat, but it is unlikely by itself to explain a change from 94 to 156 mg/dL.

Does this look like familial hypercholesterolemia?

• You are 33 years old.
• You have repeatedly had untreated LDL-C around or above 190 mg/dL.
• This has persisted despite changes in statin use.
• LDL-C at or above 190 mg/dL is considered severe hypercholesterolemia, and inherited causes should be considered after secondary causes are excluded.

• Parent, brother, sister, or child with markedly high LDL
• Heart attack, bypass surgery, angioplasty, stroke, or sudden cardiac death before age 55 in a male relative or before age 65 in a female relative
• Tendon lumps/thickening, especially Achilles tendon xanthomas
• Corneal arcus at a young age
• Multiple family members taking cholesterol medicines

Most important practical conclusion

Discuss this plan with your clinician

1. Do not stop or restart cholesterol medicine repeatedly without medical advice.
2. Confirm the prescribed treatment and take it consistently as directed.
3. Repeat a fasting lipid panel 4-12 weeks after stable, daily treatment.
4. Check:
   • TSH and free T4
   • HbA1c and fasting glucose
   • Creatinine/eGFR and urine protein or urine albumin-creatinine ratio
   • Liver enzymes, bilirubin, alkaline phosphatase
   • ApoB
   • Lipoprotein(a), or Lp(a), at least once
5. Review all medicines, alcohol intake, supplements, gym products, and anabolic steroid/testosterone use.
6. Obtain lipid profiles for first-degree relatives, particularly parents and siblings.
7. If LDL remains high despite verified regular treatment, your clinician may consider increasing statin intensity or adding a non-statin medicine such as ezetimibe. This choice should be individualized.

One correction to the timeline

“LDL after approximately 15 days off rosuvastatin: near-untreated / functionally untreated.”

Updated conclusion

• no obesity
• normal HbA1c/glucose
• no insulin resistance
• no metabolic syndrome pattern

How thyroid dysfunction raises LDL

Low thyroid hormone effect
        ↓
Fewer / less active liver LDL receptors
        ↓
Reduced removal of LDL from blood
        ↓
Higher LDL cholesterol and total cholesterol

Can subclinical hypothyroidism alone cause LDL 190-200?

• TSH is elevated
• Free T4 remains normal

Subclinical hypothyroidism
     = plausible LDL amplifier

Persistent LDL 175-200 despite corrected thyroid status
     = needs evaluation as primary / inherited high LDL

How it fits your timeline

February 2025: LDL 192 untreated

June 2025: LDL 94 on rosuvastatin 5 mg

• Consistent rosuvastatin use
• Improved thyroid status if Thyronorm had started and TSH had normalized
• Both together

November 2025: LDL 175 after stopping rosuvastatin

May 2026: LDL 156 while supposedly taking rosuvastatin

1. Was rosuvastatin taken every day in the preceding 4-8 weeks?
2. Was the prescription and tablet strength unchanged?
3. What were TSH and free T4 on the same date?
4. Were there new medicines, major diet changes, weight changes, alcohol intake, or a high saturated-fat/keto-type diet?
5. Was the sample fasting, and what were the triglycerides?

August 2026: LDL 200 after 15 days off rosuvastatin

What should be checked now

Lipid profile after at least 4-12 weeks of consistent daily rosuvastatin, with documented normal TSH and free T4.

Take Thyronorm correctly

Bottom line

• Primary severe LDL elevation is likely
• Subclinical hypothyroidism may have worsened it
• No obesity or insulin resistance makes metabolic dyslipidemia less likely as the main cause
• The LDL fall to 94 proves rosuvastatin can be highly effective for you
• The key next step is stable thyroid control plus uninterrupted lipid treatment, followed by repeat testing and assessment for familial hypercholesterolemia.

Provisional assessment: you meet possible FH criteria by the Dutch score, but not yet definite or probable FH

• Male, age 33
• Highest reliably untreated LDL-C: 200 mg/dL
• Other untreated LDL-C values: 192 and 175 mg/dL
• Good response to rosuvastatin 5 mg: LDL 192 to 94 mg/dL
• Subclinical hypothyroidism existed but is reported corrected with Thyronorm
• No obesity, diabetes, or insulin resistance
• No family history, tendon xanthomas, corneal arcus, or premature cardiovascular disease has yet been provided

1. Dutch Lipid Clinic Network (DLCN) score

DLCN interpretation

2. Simon Broome criteria

• Total cholesterol above 290 mg/dL, or
• LDL-C above 190 mg/dL

Does corrected hypothyroidism change this?

• TSH is in target range on a stable Thyronorm dose
• Free T4 is normal
• Lipids are measured after stable thyroid correction
• Kidney protein loss, cholestatic liver disease, and medication effects have been excluded

My clinical interpretation

Possible heterozygous familial hypercholesterolemia / severe primary hypercholesterolemia, pending formal exclusion of secondary causes and family assessment.

What information could upgrade your score?

To “probable FH” by DLCN

• LDL 200 mg/dL: 3 points
• First-degree relative with premature coronary disease or LDL above the 95th percentile: +1 point
• Corneal arcus before age 45: +4 points

To “definite FH” by DLCN

• A pathogenic mutation in LDLR, APOB, or PCSK9: +8 points by itself
• Tendon xanthomas: +6 points, which combined with your LDL score totals 9
• A sufficiently strong combination of family history, early vascular disease, and physical signs

Information to collect before your appointment

1. Family lipid results
   • Parents, siblings, and children if applicable
   • Ask specifically whether anyone has LDL-C above 190 mg/dL or takes statins for high cholesterol.
2. Premature cardiovascular events in relatives
   • Heart attack, angioplasty, bypass, stroke, sudden cardiac death:
     • Men younger than 55
     • Women younger than 60-65, depending on the criterion used
3. Physical examination
   • Achilles tendon thickening or nodules
   • Tendon xanthomas over knuckles, elbows, knees
   • Corneal arcus before age 45
4. Tests
   • Fasting lipid profile after stable, consistent therapy
   • TSH and free T4
   • ApoB
   • One-time Lp(a)
   • Kidney function and urine albumin/protein
   • Liver enzymes and bilirubin
   • Consider an FH gene panel if secondary causes are excluded

• Father: CAD, heart attack, angioplasty, bypass, or sudden cardiac death before age 55
• Mother: the same event before age 60
• Maternal grandmother: second-degree relative, typically counts if coronary disease occurred before age 60 under the Dutch criteria

How this changes your score

• Untreated LDL-C 200 mg/dL: 3 DLCN points

• First-degree relative with premature CAD: +1 point
• Total: 4 points
• Result: still Possible FH by DLCN, but stronger clinical suspicion.

Simon Broome criteria

• Your father had MI/CAD before age 60, or
• Your mother had MI/CAD before age 60, or
• Your maternal grandmother had MI/CAD before age 50.

• DLCN: 3 points from maximum untreated LDL-C 200 mg/dL (5.0-6.4 mmol/L)
  • Classification: possible FH
• CAD in both parents and maternal grandmother raises suspicion, but it only changes formal scoring if the events meet the relevant definitions of premature CAD.

Severe primary hypercholesterolemia, phenotype suspicious for heterozygous FH; current DLCN score 3 pending confirmation of premature first-degree CAD, physical stigmata, family lipid phenotyping, Lp(a), and consideration of genetic testing.

Core dietary prescription

• Very low in saturated and trans fats
• High in vegetables, fruits, pulses, whole grains, nuts, and soluble fibre
• Replace animal/tropical fats with unsaturated plant oils
• Limit refined carbohydrate and alcohol because triglycerides are mildly elevated

Practical daily plan

On waking

• Thyronorm: take with water on an empty stomach, at the same time daily.
• Wait 30-60 minutes before tea, coffee, breakfast, or other medications.
• Keep calcium, iron, antacids, and multivitamins at least 4 hours away from levothyroxine, unless endocrinology advises otherwise.

Breakfast

• Oats porridge with skim/low-fat milk or unsweetened soy milk, fruit, and 1 tablespoon ground flaxseed
• Vegetable oats upma or oats chilla
• Idli with sambar and vegetables, avoiding ghee/butter
• Whole-wheat/whole-grain roti with dal/vegetable
• Besan chilla with vegetables
• Unsweetened curd, preferably low fat, with fruit and oats

• Butter toast, cheese-heavy sandwiches
• Paratha with ghee/butter
• Poori, bhatura, vada
• Bakery cakes, puffs, doughnuts, biscuits
• Coconut chutney in large portions if prepared with substantial coconut
• Sugary tea/coffee and fruit juice

Mid-morning

• One whole fruit: apple, guava, orange, pear, papaya, berries, or seasonal fruit
• A small handful of unsalted nuts: about 25-30 g/day total, such as almonds, walnuts, pistachios, peanuts
• Do not use salted, fried, sugar-coated, or ghee-roasted nuts.

Lunch and dinner: plate method

• Half the plate: non-starchy vegetables, salad, sambar vegetables, leafy vegetables, bhindi, beans, gourds, cabbage, cauliflower, etc.
• One-quarter: protein, such as dal, chana, rajma, sprouts, soy/tofu, fish, egg whites/eggs in moderation, or skinless poultry.
• One-quarter: high-fibre carbohydrate, such as whole-wheat roti, jowar/bajra/ragi roti, brown/red rice, millets, quinoa, or smaller portions of regular rice.

• 2 whole-wheat/millet rotis + dal + vegetable sabzi + salad
• Brown/red rice or controlled white-rice portion + sambar + vegetable + curd
• Rajma/chole with salad and one or two phulkas, not butter naan
• Grilled fish/chicken with vegetables and whole grains
• Tofu/paneer substitute with vegetables. Prefer tofu or low-fat paneer rather than full-fat paneer.

Cooking fats

• Groundnut oil
• Mustard oil
• Rice bran oil
• Olive oil where practical
• Sunflower/safflower oil can be used in rotation

Specific LDL-lowering foods

1. Soluble or viscous fibre, daily

• Oats and barley
• Dal, chana, rajma, lobia, peas
• Apples, citrus fruits, guava
• Okra and eggplant
• Psyllium husk (isabgol)

2. Nuts and seeds

• 25-30 g/day unsalted mixed nuts
• 1 tablespoon/day ground flaxseed or chia seed can be added to oats, curd, or salads
• Walnuts are a useful option

3. Plant protein

• Dal, legumes, sprouts
• Soybeans, tofu, soy chunks
• Unsweetened soy milk
• Chana, rajma, black beans

4. Plant sterols and stanols

Protein choices

Prefer

• Dal, pulses, soy, tofu
• Fish 1-2 times weekly, especially oily fish if locally available
• Skinless poultry
• Low-fat dairy in controlled portions
• Eggs can usually fit into a heart-healthy pattern, but avoid cooking them in butter/ghee and avoid pairing them with processed meats.

Limit

• Red meat: ideally occasional and small portions
• Mutton, beef, pork belly, organ meats
• Processed meats: sausages, salami, bacon, kebabs with visible fat
• Full-fat paneer, cheese, cream, butter, ghee
• Fried chicken/fish and restaurant gravies rich in butter/cream

Addressing triglycerides of 173 mg/dL

• Sugar-sweetened drinks
• Fruit juice, including “fresh” juice
• Sweets, desserts, bakery products
• Large portions of polished rice, maida, noodles, white bread
• Alcohol. Best recommendation is avoid or minimize, especially until triglycerides are consistently normal.
• Late-night heavy meals and habitual snacking

Daily movement and lifestyle

Exercise

• Aerobic: at least 150 minutes/week moderate-intensity activity, such as brisk walking, cycling, swimming, or jogging.
• A practical target: 30-45 minutes brisk walking on 5-6 days/week.
• Resistance training: 2-3 non-consecutive days/week, using bodyweight, bands, or weights.
• Break prolonged sitting every 30-60 minutes with 2-5 minutes of walking or movement.
• Aim for 7,000-10,000 steps/day if practical, building gradually.

Tobacco and alcohol

• No smoking, vaping, chewing tobacco, or nicotine products.
• Avoid alcohol or keep it minimal, particularly while triglycerides are above target.

Sleep and stress

• Sleep target: 7-9 hours/night
• Evaluate snoring, witnessed apneas, and excessive daytime sleepiness. Untreated sleep apnea can worsen cardiometabolic risk.
• Use a sustainable stress strategy: walking, structured exercise, yoga, breathing exercises, counselling, or mindfulness.

What not to recommend

• Do not recommend keto, carnivore, butter coffee, ghee-heavy “low-carb” diets, or routine coconut/palm-oil-heavy diets in this phenotype. LDL can rise substantially in lean individuals on low-carbohydrate/high-saturated-fat diets, as noted in a 2024 meta-analysis.
• Do not allow “normal weight” or “normal insulin resistance markers” to be interpreted as protection from LDL-mediated ASCVD.
• Do not use nutraceuticals or supplements as substitutes for evidence-based LDL-lowering therapy.
• Do not start red yeast rice alongside a statin without supervision because product dose and safety are unreliable.

Clinician-oriented follow-up

1. Re-establish uninterrupted statin adherence, using the prescribed dose and timing.
2. Ensure euthyroidism with documented TSH and free T4.
3. Obtain fasting lipid profile after 4-12 weeks on stable therapy.
4. Record fasting ApoB and one-time Lp(a).
5. Check BP, tobacco exposure, diet history, physical activity, sleep apnea symptoms, renal/liver status.
6. In suspected HeFH, lifestyle counselling should be framed as additive. The expected LDL reduction from diet is meaningful, but unlikely to bring an untreated LDL of 175-200 mg/dL to a safe range without pharmacotherapy.

Lipaglyn: mechanism and clinical use

• Predominant PPAR-alpha activity
• Modest PPAR-gamma activity

Mechanism of action

1. PPAR-alpha activation: main lipid effect

↑ fatty-acid uptake and beta-oxidation
↓ hepatic triglyceride synthesis
↓ hepatic VLDL production
↑ lipoprotein lipase-mediated triglyceride clearance
↓ ApoC-III activity/expression
↓ circulating triglycerides and VLDL

• Marked triglyceride reduction
• Reduction in VLDL-C and remnant cholesterol
• Some reduction in non-HDL-C and LDL-C may occur
• HDL-C may increase modestly

2. PPAR-gamma activation: metabolic effect

↑ insulin sensitivity
↓ circulating free fatty-acid delivery to liver
↓ hepatic triglyceride production
↓ glucose and HbA1c in type 2 diabetes

Approved / usual clinical role

Diabetic dyslipidemia or hypertriglyceridemia in adults with type 2 diabetes not adequately controlled by statin therapy.

Situations where it may be considered

Relevance to this patient

• Age 33
• Untreated LDL-C repeatedly around 175-200 mg/dL
• Triglycerides 173 mg/dL
• No obesity
• No insulin resistance
• No diabetes mentioned
• Corrected subclinical hypothyroidism
• Possible heterozygous FH phenotype
• Strong family burden of CAD

Lipaglyn is not the key drug for this profile

Why

1. Confirm adherence and thyroid euthyroidism
2. Use an appropriate, sustained statin regimen
3. Assess response after 4-12 weeks
4. Escalate LDL-directed therapy when indicated

Practical prescribing perspective

Saroglitazar has a triglyceride- and glucose-directed mechanism through dual PPAR-alpha/gamma activity. In this patient with marked LDL-predominant dyslipidemia and suspected HeFH, it does not address the principal atherogenic abnormality and should not displace optimized LDL-lowering therapy.

Safety and monitoring considerations

• Liver enzymes and bilirubin
• Renal function
• Glycaemic status
• Edema or heart failure history
• Concomitant drugs
• Alcohol exposure and fatty liver disease
• Pregnancy potential where relevant

Bottom line

• It is not a substitute for rosuvastatin or other LDL-lowering therapy
• It has no central role unless a separate diabetic/metabolic hypertriglyceridemia or locally approved liver indication emerges
• The treatment focus should remain on durable LDL reduction, ApoB/Lp(a) assessment, family screening, thyroid control, and formal FH evaluation.

Revised interpretation

• Lower fasting insulin and HOMA-IR
• Better fasting glucose and HbA1c, if elevated
• Lower triglycerides and VLDL-C
• Improvement in fatty liver markers, if steatosis was present
• A modest improvement in non-HDL-C and sometimes LDL-C

How it changes the dyslipidemia assessment

Insulin resistance
   ↓
More adipose free-fatty-acid delivery to liver
   ↓
Increased hepatic triglyceride synthesis and VLDL secretion
   ↓
Higher triglycerides, VLDL/remnants, non-HDL-C
   ↓
Potentially more small dense LDL

• Repeated untreated LDL-C of 175-200 mg/dL
• LDL-C above 190 mg/dL on at least two occasions
• Marked LDL predominance despite lack of obesity
• Multigenerational CAD history
• LDL-C reduction from 192 to 94 mg/dL with rosuvastatin

Severe primary hypercholesterolemia with prior insulin resistance and treated subclinical hypothyroidism, phenotype suspicious for heterozygous familial hypercholesterolemia.

“Pure FH with no metabolic contribution.”

Implication for Lipaglyn

Reassess the current state objectively

• Fasting glucose, HbA1c
• Fasting insulin and calculated HOMA-IR, using the same assay/lab where possible
• Waist circumference and BP
• ALT/AST/GGT and liver ultrasound or controlled attenuation parameter if fatty liver is suspected
• Fasting triglycerides, non-HDL-C, ApoB
• TSH and free T4

Updated clinical note wording

33-year-old male with severe untreated LDL-predominant hypercholesterolemia (LDL-C 175-200 mg/dL), previous insulin resistance improved on saroglitazar, and treated subclinical hypothyroidism. Rosuvastatin 5 mg previously reduced LDL-C from 192 to 94 mg/dL. Persistent severe baseline LDL elevation, together with multigenerational CAD, remains suspicious for HeFH or polygenic severe hypercholesterolemia. Prior insulin resistance may have contributed to VLDL/TG elevation but does not adequately account for the magnitude and persistence of LDL-C elevation.